Now live: FDA · Health Canada · EU/UK 1169 · Gulf GSO · FSANZ · Swiss LIV · India FSSAI · Eurasian TR CU 022 · East African EAS 38 · CARICOM CRS 5 · MERCOSUR / ANVISA · Japan CAA label formats · true-scale KLD dielines · multilingual ingredient intelligence
regulatory

Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases

EFSA (European Food Safety Authority) · European Union · published 29 Sep 2026

Deadline: 2027-04-13 , 2027-09-22 Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and

Read the official notice →

Source: EFSA (European Food Safety Authority) · EFSA reuse policy (attribution). This is a short, attributed summary; the full authoritative text lives on the authority’s own site. LabelYog does not author or endorse it — confirm compliance against the destination market’s official source.

More from European Union

What this means for your label

A notice like this changes what a pack must carry. These are the rules we build against, starting with EU 1169.

← All food-authority news